Build synthetic arm to target new indication and subpopulation of interest

Synthetic control arms: reducing the burden of clinical trials

One of Okeiro's most transformative applications is the creation of synthetic control arms for clinical trials.

Generate historical controls with unprecedented precision

Okeiro can create matched control cohorts that mirror the characteristics of the intervention group. This approach:

• Reduces the need for prospective standard-of-care control groups
• Decreases overall trial costs and timelines
• Enables trials in rare conditions where traditional control arms are impractical

Hypothesis generation and rapid testing

When signals suggesting repurposing opportunities are detected, Okeiro enables:

• Controlled retrospective analyses with propensity score matching
• Design and implementation of prospective studies to confirm findings
• Adaptive protocol development based on emerging real-world data

Multimodal biomarker identification

By integrating diverse data types, Okeiro can identify complex biomarker signatures that predict treatment response:

• Laboratory value patterns that correlate with therapeutic outcomes
• Imaging characteristics associated with differential response
• Medication interaction profiles that modify treatment effectiveness
• Temporal changes in clinical parameters that signal response trajectory

Patient-centered research design

By integrating with clinical care, Okeiro supports research approaches that:

• Minimize additional burden on patients
• Capture outcomes that matter most to patients
• Adapt to individual patient characteristics and preferences
• Enable participation regardless of geographic location or center type

Accelerated access to innovation

The platform's approach dramatically compresses the timeline from discovery to implementation:

• Potential applications are identified through real-world signal detection
• Validation occurs within existing care networks
• Implementation tools are built directly into the platform
• Outcomes monitoring begins immediately upon implementation

Conclusion

The Okeiro platform represents a paradigm shift in how we approach evidence generation for transplant and end-stage disease management. By leveraging real-world data to build synthetic control arms, identify repurposing opportunities, and predict treatment response, Okeiro transforms the traditional research model into a seamless extension of patient care.

For patients with complex conditions like organ failure and transplantation, this integrated approach promises to accelerate access to novel therapies and optimize existing treatment pathways. As the platform continues to evolve, its impact will extend beyond individual treatment decisions to reshape how we conceptualize the relationship between clinical care and clinical research.

The future of medicine lies not in occasional clinical trials disconnected from routine care, but in learning healthcare systems that continuously generate and apply evidence. Okeiro stands at the forefront of this revolution, particularly for the vulnerable populations facing transplantation and end-stage organ disease.